The heptad repeat 2 domain is a major determinant for enhanced human immunodeficiency virus type 1 (HIV-1) fusion and pathogenicity of a highly pathogenic HIV-1 Env

Journal of Virology

Volumn 83, Issue 22, 2009, Pages 11715-11725

  Sivaraman, Vijay ^a   Zhang, Liguo ^a   Meissner, Eric G ^a,b   Jeffrey, Jerry L ^a   Su, Lishan ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4+ T LYMPHOCYTE; CELL DEATH; CHIMERA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; EX VIVO STUDY; FUSION GENE; GENE MAPPING; GENE MUTATION; HEPTAD REPEAT 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; LYMPHOCYTE DEPLETION; NONHUMAN; NUCLEOTIDE REPEAT; PATHOGENICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; T CELL DEPLETION; THYMUS; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, CXCR4; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350314352     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00649-09     Document Type: Article

References (40)

1. Beaumont, T., E. Quakkelaar, A. van Nuenen, R. Pantophlet, and H. Schuitemaker. 2004. Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J. Virol. 78:5651-5657. (Pubitemid 38661652)
2. Bonyhadi, M. L., L. Rabin, S. Salimi, D. A. Brown, J. Kosek, J. M. McCune, and H. Kaneshima. 1993. HIV induces thymus depletion in vivo. Nature 363:728-732. (Pubitemid 23227651)
3. Brandt, S. M., R. Mariani, A. U. Holland, T. J. Hope, and N. R. Landau. 2002. Association of chemokine-mediated block to HIV entry with coreceptor internalization. J. Biol. Chem. 277:17291-17299.
4. Cayabyab, M., D. Rohne, G. Pollakis, C. Mische, T. Messele, A. Abebe, B. Etemad-Moghadam, P. Yang, S. Henson, M. Axthelm, J. Goudsmit, N. L. Letvin, and J. Sodroski. 2004. Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian clade C HIV type 1 isolate. AIDS Res. Hum. Retrovir. 20:27-40.
5. Chan, D. C., D. Fass, J. M. Berger, and P. S. Kim. 1997. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
6. Coffield, V. M., Q. Jiang, and L. Su. 2003. A genetic approach to inactivating chemokine receptors using a modified viral protein. Nat. Biotechnol. 21: 1321-1327.
7. Connor, R. I., B. K. Chen, S. Choe, and N. R. Landau. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
8. Doms, R. W., P. L. Earl, S. Chakrabarti, and B. Moss. 1990. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus Env proteins possess a functionally conserved assembly domain. J. Virol. 64: 3537-3540.
9. Dunfee, R. L., E. R. Thomas, P. R. Gorry, J. Wang, J. Taylor, K. Kunstman, S. M. Wolinsky, and D. Gabuzda. 2006. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. USA 103:15160-15165.
10. Earl, P. L., R. W. Doms, and B. Moss. 1990. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 87:648-652.
11. + T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J. Virol. 75:5646-5655.
12. + T-cell depletion in macaques infected by a simian-human immunodeficiency virus. Vaccine 20:1934-1937.
13. Feinberg, M. B., and W. C. Greene. 1992. Molecular insights into human immunodeficiency virus type 1 pathogenesis. Curr. Opin. Immunol. 4:466-474.
14. Gallo, R. C., and A. Garzino-Demo. 2001. Some recent results on HIV pathogenesis with implications for therapy and vaccines. Cell Mol. Biol. 47:1101-1104.
15. Garg, H., and R. Blumenthal. 2008. Role of HIV Gp41 mediated fusion/ hemifusion in bystander apoptosis. Cell Mol. Life Sci. 65:3134-3144.
16. Garzino-Demo, A., A. L. DeVico, and R. C. Gallo. 1998. Chemokine receptors and chemokines in HIV infection. J. Clin. Immunol. 18:243-255.
17. cdc2 activity. J. Virol. 69:6705-6711.
18. + T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions. J. Virol. 79:6299-6311.
19. Jiang, S., Q. Zhao, and A. K. Debnath. 2002. Peptide and non-peptide HIV fusion inhibitors. Curr. Pharm. Des. 8:563-580.
20. Kaneshima, H., C. C. Shih, R. Namikawa, L. Rabin, H. Outzen, S. G. Machado, and J. M. McCune. 1991. Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse. Proc. Natl. Acad. Sci. USA 88:4523-4527.
21. + T cells: role of lymphoid tissue microenvironment and effect of immunomodulating agents. AIDS Res. Hum. Retrovir. 19:847-856.
22. + T cells isolated from HIV-infected individuals in the absence of markers of cellular activation or apoptosis. J. Immunol. 170:2449-2455.
23. Liu, S., H. Lu, J. Niu, Y. Xu, S. Wu, and S. Jiang. 2005. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J. Biol. Chem. 280: 11259-11273.
24. Lu, M., and P. S. Kim. 1997. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 15:465-471.
25. Malashkevich, V. N., D. C. Chan, C. T. Chutkowski, and P. S. Kim. 1998. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc. Natl. Acad. Sci. USA 95:9134-9139.
26. Meissner, E. G., V. M. Coffield, and L. Su. 2005. Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry. Virology 336:184-197.
27. Meissner, E. G., K. M. Duus, F. Gao, X. F. Yu, and L. Su. 2004. Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology 328:74-88.
28. Meissner, E. G., K. M. Duus, R. Loomis, R. D'Agostin, and L. Su. 2003. HIV-1 replication and pathogenesis in the human thymus. Curr. HIV Res. 1:275-285.
29. Meissner, E. G., L. Zhang, S. Jiang, and L. Su. 2006. Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. J. Virol. 80:11019-11030.
30. Miller, E. D., K. M. Duus, M. Townsend, Y. Yi, R. Collman, M. Reitz, and L. Su. 2001. Human immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation of in vivo replication from macrophage tropism. J. Virol. 75:8498-8506.
31. Parren, P. W., M. C. Gauduin, R. A. Koup, P. Poignard, P. Fisicaro, D. R. Burton, and Q. J. Sattentau. 1997. Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol. Lett. 57:105-112.
32. Stanley, S. K., J. M. McCune, H. Kaneshima, J. S. Justement, M. Sullivan, E. Boone, M. Baseler, J. Adelsberger, M. Bonyhadi, J. Orenstein, et al. 1993. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J. Exp. Med. 178:1151-1163.
33. Su, L., H. Kaneshima, M. L. Bonyhadi, R. Lee, J. Auten, A. Wolf, B. Du, L. Rabin, B. H. Hahn, E. Terwilliger, and J. M. McCune. 1997. Identification of HIV-1 determinants for replication in vivo. Virology 227:45-52. (Pubitemid 27241054)
34. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108. (Pubitemid 26029030)
35. Vishwanathan, S. A., and E. Hunter. 2008. Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J. Virol. 82:5118-5126.
36. Wang, W. K., M. Y. Chen, C. Y. Chuang, K. T. Jeang, and L. M. Huang. 2000. Molecular biology of human immunodeficiency virus type 1. J. Microbiol. Immunol. Infect. 33:131-140.
37. Weissenhorn, W., S. A. Wharton, L. J. Calder, P. L. Earl, B. Moss, E. Aliprandis, J. J. Skehel, and D. C. Wiley. 1996. The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J. 15:1507-1514. (Pubitemid 26112372)
38. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
39. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888. (Pubitemid 28299385)
40. Yu, X. F., Z. Wang, D. Vlahov, R. B. Markham, H. Farzadegan, and J. B. Margolick. 1998. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users. J. Infect. Dis. 178:388-396.